Loading…
RNXT
RenovoRx, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 75989R107
$1.67+12.84%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
- Market cap
- $75.37M
- P/E
- —
- Forward P/E
- —
- P/B
- 8.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.35
- ROE
- -125.23%
- Profit margin
- 0.00%
- Revenue growth
- +115.40%
- Beta
- 0.99
- 52-week high
- $1.68
- 52-week low
- $0.70
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -68.0% over 5Y.
today you would have $274.83▼ -72.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $0.84 | $1.29 | $2.29 | $2.35 | $4.84 | |
| P/S | — | 33.7x | 1096.4x | — | — | — |
| P/B | 7.0x | 7.0x | 10.5x | 12.9x | 3.5x | 2.8x |
| EPS | -$0.32 | -$0.40 | -$0.99 | -$1.09 | -$1.21 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NRXSNeuraxis, INC | $6.00 | — | 11.1x | — | -139.76% | $75.35M |
| LONALeonaBio, Inc. | $7.94 | — | 2.2x | — | -431.39% | $74.81M |
| ELTXElicio Therapeutics, Inc. | $2.84 | — | 7.8x | — | -774.56% | $74.64M |
| OSTXOS Therapies Inc | $1.64 |
About the company
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
- 17
- Mountain View, United States
Company description provided by Yahoo Finance.